Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGFRL1 | Q5TC84 | 10/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9982481 | 0.86 | DHFR (0.44) | OGFRL1OPRM1OPRK1OPRD1RPS6KB1 | |
| SCHEMBL8630899 | 0.82 | OPRM1 (0.49) | OGFRL1OPRM1OPRK1OPRD1RPS6KB1 | |
| SCHEMBL6196424 | 0.82 | RPS6KB1 (0.58) | OGFRL1OPRM1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL21148134 | 0.82 | RPS6KB1 (0.58) | OGFRL1OPRM1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL2929873 | 0.82 | RPS6KB1 (0.58) | OGFRL1OPRM1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL6198016 | 0.82 | RPS6KB1 (0.58) | OGFRL1OPRM1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL6196431 | 0.82 | RPS6KB1 (0.58) | OGFRL1OPRM1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL21311236 | 0.81 | RPS6KB1 (0.50) | OGFRL1OPRM1OPRK1OPRD1RPS6KB1 | |
| SCHEMBL21311255 | 0.80 | OPRM1 (0.59) | OGFRL1OPRM1OPRK1OPRD1L3MBTL1 | |
| SCHEMBL11716653 | 0.80 | OPRM1 (0.52) | OPRM1OPRK1OPRD1CYP2D6CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | OGFRL1 172/4885OPRM1 956/4885OPRK1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.